Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Influenza A Subtype H5N1 Infection
Interventions
BIOLOGICAL

IVACFLU-A/H5N1, 7.5 mcg

Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.

BIOLOGICAL

IVACFLU-A/H5N1, 15 mcg

Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose

OTHER

Placebo Comparator

PBS, pH 7.2 in 0.5 mL single-dose vials.

Trial Locations (1)

Unknown

Ben Luc Health Center, Bến Lức

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Department of Health and Human Services

FED

collaborator

World Health Organization

OTHER

collaborator

Institut Pasteur

INDUSTRY

collaborator

PATH

OTHER

lead

Institute of Vaccines and Medical Biologicals, Vietnam

INDUSTRY

NCT02171819 - Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1 | Biotech Hunter | Biotech Hunter